ARTICLE | Clinical News
Paloxi palonosetron regulatory update
April 13, 2009 7:00 AM UTC
The National Comprehensive Cancer Network (NCCN) updated its clinical practice guidelines in oncology on antiemesis to recommend palonosetron as the preferred serotonin (5-HT3) receptor antagonist fo...